Pfizer Files 8K - Changes Executive Management
09 February 2016 - 9:51AM
Dow Jones News
Pfizer Inc. (PFE) filed a Form 8K - Changes in Company Executive
Management - with the U.S Securities and Exchange Commission on
February 08, 2016.
On February 8, 2016, Pfizer Inc. (the "Company") announced that
Geno Germano, Group President, Global Innovative Pharma Business,
will be leaving the Company. The Company also announced that,
effective immediately and through the closing of the pending
transaction between Pfizer and Allergan plc ("Allergan"), Pfizer's
Global Innovative Pharma business and its Vaccines, Oncology and
Consumer Healthcare business will operate separately under the
leadership of Albert Bourla, currently Group President, Vaccines,
Oncology and Consumer Healthcare. The Company also announced the
expected executive leadership team for the combined Pfizer-Allergan
organization upon closing of the pending transaction with
Allergan.
The related press release is filed herewith as Exhibit 99.1 and
is incorporated herein by reference.
The full text of this SEC filing can be retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000007800316000058/n8k2516.htm
Any exhibits and associated documents for this SEC filing can be
retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000007800316000058/0000078003-16-000058-index.htm
Public companies must file a Form 8-K, or current report, with
the SEC generally within four days of any event that could
materially affect a company's financial position or the value of
its shares.
(END) Dow Jones Newswires
February 08, 2016 17:36 ET (22:36 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024